661 related articles for article (PubMed ID: 16391708)
1. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
2. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Diep QN; Benkirane K; Amiri F; Cohn JS; Endemann D; Schiffrin EL
J Mol Cell Cardiol; 2004 Feb; 36(2):295-304. PubMed ID: 14871557
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
4. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.
Tostes RC; Touyz RM; He G; Chen X; Schiffrin EL
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():25S-30S. PubMed ID: 12193048
[TBL] [Abstract][Full Text] [Related]
5. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
6. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Min LJ; Mogi M; Iwanami J; Li JM; Sakata A; Fujita T; Tsukuda K; Iwai M; Horiuchi M
Cardiovasc Res; 2007 Dec; 76(3):506-16. PubMed ID: 17706954
[TBL] [Abstract][Full Text] [Related]
8. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.
Letavernier E; Perez J; Bellocq A; Mesnard L; de Castro Keller A; Haymann JP; Baud L
Circ Res; 2008 Mar; 102(6):720-8. PubMed ID: 18258859
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
10. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism.
Neves MF; Virdis A; Schiffrin EL
J Hypertens; 2003 Jan; 21(1):189-98. PubMed ID: 12544451
[TBL] [Abstract][Full Text] [Related]
11. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.
Brilla CG; Zhou G; Matsubara L; Weber KT
J Mol Cell Cardiol; 1994 Jul; 26(7):809-20. PubMed ID: 7966349
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.
Li X; Meng Y; Wu P; Zhang Z; Yang X
Regul Pept; 2007 Jan; 138(1):15-25. PubMed ID: 16971004
[TBL] [Abstract][Full Text] [Related]
14. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.
Brilla CG; Matsubara LS; Weber KT
J Mol Cell Cardiol; 1993 May; 25(5):563-75. PubMed ID: 8377216
[TBL] [Abstract][Full Text] [Related]
15. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade.
Ramires FJ; Sun Y; Weber KT
J Mol Cell Cardiol; 1998 Mar; 30(3):475-83. PubMed ID: 9515025
[TBL] [Abstract][Full Text] [Related]
16. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
Erne P
Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
[TBL] [Abstract][Full Text] [Related]
17. Induction of cardiac fibrosis by aldosterone.
Lijnen P; Petrov V
J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
[TBL] [Abstract][Full Text] [Related]
18. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.
Müller DN; Mervaala EM; Dechend R; Fiebeler A; Park JK; Schmidt F; Theuer J; Breu V; Mackman N; Luther T; Schneider W; Gulba D; Ganten D; Haller H; Luft FC
Am J Pathol; 2000 Jul; 157(1):111-22. PubMed ID: 10880382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
